Cargando…
Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study
Sputnik-V (Gam-COVID-Vac) is a heterologous, recombinant adenoviral (rAdv) vector-based, COVID-19 vaccine now used in > 70 countries. Yet there is a shortage of data on this vaccine's performance in diverse populations. Here, we performed a prospective cohort study to assess the reactogenici...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342835/ https://www.ncbi.nlm.nih.gov/pubmed/35915123 http://dx.doi.org/10.1038/s41598-022-17514-3 |
_version_ | 1784760905533227008 |
---|---|
author | Yegorov, Sergey Kadyrova, Irina Negmetzhanov, Baurzhan Kolesnikova, Yevgeniya Kolesnichenko, Svetlana Korshukov, Ilya Baiken, Yeldar Matkarimov, Bakhyt Miller, Matthew S. Hortelano, Gonzalo H. Babenko, Dmitriy |
author_facet | Yegorov, Sergey Kadyrova, Irina Negmetzhanov, Baurzhan Kolesnikova, Yevgeniya Kolesnichenko, Svetlana Korshukov, Ilya Baiken, Yeldar Matkarimov, Bakhyt Miller, Matthew S. Hortelano, Gonzalo H. Babenko, Dmitriy |
author_sort | Yegorov, Sergey |
collection | PubMed |
description | Sputnik-V (Gam-COVID-Vac) is a heterologous, recombinant adenoviral (rAdv) vector-based, COVID-19 vaccine now used in > 70 countries. Yet there is a shortage of data on this vaccine's performance in diverse populations. Here, we performed a prospective cohort study to assess the reactogenicity and immunologic outcomes of Sputnik-V vaccination in Kazakhstan. COVID-19-free participants (n = 82 at baseline) were followed at day 21 after Sputnik-V dose 1 (rAd5) and dose 2 (rAd26). Self-reported local and systemic adverse events were captured using questionnaires. Blood and nasopharyngeal swabs were collected to perform SARS-CoV-2 diagnostic and immunologic assays. We observed that most of the reported adverse events were mild-to-moderate injection site or systemic reactions, no severe or potentially life-threatening conditions were reported, and dose 1 appeared to be more reactogenic than dose 2. The seroconversion rate was 97% post-dose 1, remaining the same post-dose 2. The proportion of participants with detectable virus neutralization was 83% post-dose 1, increasing to 98% post-dose 2, with the largest relative increase observed in participants without prior COVID-19 exposure. Dose 1 boosted nasal S-IgG and S-IgA, while the boosting effect of dose 2 on mucosal S-IgG, but not S-IgA, was only observed in subjects without prior COVID-19. Systemically, vaccination reduced serum levels of growth regulated oncogene (GRO), which correlated with an elevation in blood platelet count. Overall, Sputnik-V dose 1 elicited both blood and mucosal SARS-CoV-2 immunity, while the immune boosting effect of dose 2 was minimal. Thus, adjustments to the current vaccine dosing regimen are necessary to optimize immunization efficacy and cost-effectiveness. While Sputnik-V reactogenicity is similar to that of other COVID-19 vaccines, the induced alterations to the GRO/platelet axis warrant investigation of the vaccine’s effects on systemic immunology. |
format | Online Article Text |
id | pubmed-9342835 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-93428352022-08-02 Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study Yegorov, Sergey Kadyrova, Irina Negmetzhanov, Baurzhan Kolesnikova, Yevgeniya Kolesnichenko, Svetlana Korshukov, Ilya Baiken, Yeldar Matkarimov, Bakhyt Miller, Matthew S. Hortelano, Gonzalo H. Babenko, Dmitriy Sci Rep Article Sputnik-V (Gam-COVID-Vac) is a heterologous, recombinant adenoviral (rAdv) vector-based, COVID-19 vaccine now used in > 70 countries. Yet there is a shortage of data on this vaccine's performance in diverse populations. Here, we performed a prospective cohort study to assess the reactogenicity and immunologic outcomes of Sputnik-V vaccination in Kazakhstan. COVID-19-free participants (n = 82 at baseline) were followed at day 21 after Sputnik-V dose 1 (rAd5) and dose 2 (rAd26). Self-reported local and systemic adverse events were captured using questionnaires. Blood and nasopharyngeal swabs were collected to perform SARS-CoV-2 diagnostic and immunologic assays. We observed that most of the reported adverse events were mild-to-moderate injection site or systemic reactions, no severe or potentially life-threatening conditions were reported, and dose 1 appeared to be more reactogenic than dose 2. The seroconversion rate was 97% post-dose 1, remaining the same post-dose 2. The proportion of participants with detectable virus neutralization was 83% post-dose 1, increasing to 98% post-dose 2, with the largest relative increase observed in participants without prior COVID-19 exposure. Dose 1 boosted nasal S-IgG and S-IgA, while the boosting effect of dose 2 on mucosal S-IgG, but not S-IgA, was only observed in subjects without prior COVID-19. Systemically, vaccination reduced serum levels of growth regulated oncogene (GRO), which correlated with an elevation in blood platelet count. Overall, Sputnik-V dose 1 elicited both blood and mucosal SARS-CoV-2 immunity, while the immune boosting effect of dose 2 was minimal. Thus, adjustments to the current vaccine dosing regimen are necessary to optimize immunization efficacy and cost-effectiveness. While Sputnik-V reactogenicity is similar to that of other COVID-19 vaccines, the induced alterations to the GRO/platelet axis warrant investigation of the vaccine’s effects on systemic immunology. Nature Publishing Group UK 2022-08-01 /pmc/articles/PMC9342835/ /pubmed/35915123 http://dx.doi.org/10.1038/s41598-022-17514-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Yegorov, Sergey Kadyrova, Irina Negmetzhanov, Baurzhan Kolesnikova, Yevgeniya Kolesnichenko, Svetlana Korshukov, Ilya Baiken, Yeldar Matkarimov, Bakhyt Miller, Matthew S. Hortelano, Gonzalo H. Babenko, Dmitriy Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study |
title | Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study |
title_full | Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study |
title_fullStr | Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study |
title_full_unstemmed | Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study |
title_short | Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study |
title_sort | sputnik-v reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342835/ https://www.ncbi.nlm.nih.gov/pubmed/35915123 http://dx.doi.org/10.1038/s41598-022-17514-3 |
work_keys_str_mv | AT yegorovsergey sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy AT kadyrovairina sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy AT negmetzhanovbaurzhan sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy AT kolesnikovayevgeniya sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy AT kolesnichenkosvetlana sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy AT korshukovilya sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy AT baikenyeldar sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy AT matkarimovbakhyt sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy AT millermatthews sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy AT hortelanogonzaloh sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy AT babenkodmitriy sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy |